Status:
COMPLETED
Second Malignant Neoplasms After Childhood ALL Therapy
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Nordic Society for Pediatric Hematology and Oncology
European Organisation for Research and Treatment of Cancer - EORTC
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
Up to 20 years
Brief Summary
Development of a second neoplasm (SMN) during or after therapy for childhood acute lymphoblastic leukemia (ALL) is a rare event generally associated with a poor prognosis. In this international study ...
Detailed Description
To explore epidemiology, potential risk factors and survival rates of second cancers occurring as the first event in childhood acute lymphoblastic leukemia the involved study groups will collect anony...
Eligibility Criteria
Inclusion
- Diagnosed with childhood acute lymphoblastic leukemia
- Diagnosis of second cancer before December 31st 2007
Exclusion
- Uncertainty if the second cancer has emerged from the same original leukemic clone
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
642 Patients enrolled
Trial Details
Trial ID
NCT01476462
Start Date
January 1 2009
End Date
December 1 2011
Last Update
May 24 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kjeld Schmiegelow
Copenhagen, Denmark, 2100